Novartis Heart Failure Drug Gains Approval In Europe

Entresto, the novel heart failure drug from Novartis, has now been approved in Europe. The company said the drug, a twice-a-day combination of sacubitril and valsartan (formerly known as LCZ 696), had been approved by the European Commission for the treatment of people with symptomatic chronic heart failure with reduced ejection fraction (HFrEF). The news follows previous approval of the drug by...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: Heart Failure People, Places & Events Entresto LCZ 696 Novartis Source Type: blogs